Read ASGCT's 2023 Q2 Landscape Analysis Field Report

The second quarterly report of 2023 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Highlights from this issue include:

• Approval of six therapies, including two gene therapies that are the first to be approved for their respective indications

• More gene therapies moving into Phase II trials in the past quarter than have in more than a year

• A six percent increase in dealmaking over the previous quarter and a quarterly high in the last year

Download the full report

Click any of the samples below to view the full report:

Related Articles